Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

New treatments in hemophilia: insights for the clinician.

Knobe K, Berntorp E.

Ther Adv Hematol. 2012 Jun;3(3):165-75. doi: 10.1177/2040620712440007.

2.
3.
4.

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.

Mancuso ME, Mannucci PM.

Drug Des Devel Ther. 2014 Mar 28;8:365-71. doi: 10.2147/DDDT.S47312. eCollection 2014. Review.

5.

Central venous access devices in patients with hemophilia.

Valentino LA, Kapoor M.

Expert Rev Med Devices. 2005 Nov;2(6):699-711. Review.

PMID:
16293097
7.

Emerging drugs for hemophilia B.

Mannucci PM, Franchini M.

Expert Opin Emerg Drugs. 2014 Sep;19(3):407-14. doi: 10.1517/14728214.2014.946010. Epub 2014 Aug 6. Review.

PMID:
25098797
8.

Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.

Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK.

Cochrane Database Syst Rev. 2011 Sep 7;(9):CD003429. doi: 10.1002/14651858.CD003429.pub4. Review.

PMID:
21901684
9.

Recombinant factor VIII in the management of hemophilia A: current use and future promise.

Powell JS.

Ther Clin Risk Manag. 2009 Apr;5(2):391-402. Epub 2009 May 20.

10.

New developments in the management of moderate-to-severe hemophilia B.

Nazeef M, Sheehan JP.

J Blood Med. 2016 Apr 1;7:27-38. doi: 10.2147/JBM.S81520. eCollection 2016. Review.

11.

A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.

Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ, Hay JW.

J Manag Care Spec Pharm. 2016 Feb;22(2):149-57. doi: 10.18553/jmcp.2016.22.2.149.

12.

Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.

Ducore JM, Miguelino MG, Powell JS.

Expert Rev Hematol. 2014 Oct;7(5):559-71. doi: 10.1586/17474086.2014.951322. Epub 2014 Aug 21.

PMID:
25142322
13.

Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.

Shapiro A.

Expert Opin Biol Ther. 2013 Sep;13(9):1287-97. doi: 10.1517/14712598.2013.819339. Review.

PMID:
23930915
14.

Extended half-life clotting factor concentrates: results from published clinical trials.

Young G, Mahlangu JN.

Haemophilia. 2016 Jul;22 Suppl 5:25-30. doi: 10.1111/hae.13028.

PMID:
27405672
15.

Inhibitor antibodies to factor VIII and factor IX: management.

Lusher JM.

Semin Thromb Hemost. 2000;26(2):179-88. Review.

PMID:
10919411
16.

Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia.

Markusic DM, Herzog RW.

J Genet Syndr Gene Ther. 2012 Jan 18;1:1-9.

17.

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.

Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G.

J Thromb Haemost. 2015 Jun;13(6):967-77. doi: 10.1111/jth.12911. Epub 2015 Apr 23.

18.

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.

Mancuso ME, Santagostino E.

J Clin Med. 2017 Mar 28;6(4). pii: E39. doi: 10.3390/jcm6040039. Review.

19.

Prevention of bleeding in hemophilia patients with high-titer inhibitors.

Leissinger CA, Konkle BA, Antunes SV.

Expert Rev Hematol. 2015 Jun;8(3):375-82. doi: 10.1586/17474086.2015.1036733. Epub 2015 May 2. Review.

PMID:
25937074
20.

Biological rationale for new drugs in the bleeding disorders pipeline.

Fogarty PF.

Hematology Am Soc Hematol Educ Program. 2011;2011:397-404. doi: 10.1182/asheducation-2011.1.397. Review.

PMID:
22160064

Supplemental Content

Support Center